How inclusive are cell lines in preclinical engineered cancer models?
Diverse factors contribute to significant and dire disparities in cancer risk and treatment outcomes. To address this, there was a call for inclusion of sex as a biological variable, which resulted in more instances of careful inclusion of sex in preclinical studies of cancer. Another variable in ca...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Company of Biologists
2022-05-01
|
| Series: | Disease Models & Mechanisms |
| Online Access: | http://dmm.biologists.org/content/15/5/dmm049520 |
| _version_ | 1818204217870909440 |
|---|---|
| author | Shreya Raghavan |
| author_facet | Shreya Raghavan |
| author_sort | Shreya Raghavan |
| collection | DOAJ |
| description | Diverse factors contribute to significant and dire disparities in cancer risk and treatment outcomes. To address this, there was a call for inclusion of sex as a biological variable, which resulted in more instances of careful inclusion of sex in preclinical studies of cancer. Another variable in cancer treatment is genetic ancestry. Although this is considered explicitly in clinical research, it is considerably neglected in preclinical studies. Preclinical research can use several 3D in vitro model systems, such as spheroids/organoids, xenografts, or other bioengineered systems that combine biomaterials and cellular material. Ultimately, the cellular base for all of these in vitro model systems is derived from human cell lines or patient samples, to investigate mechanisms of cancer and screen novel therapeutics, all of which aim to maximize successful outcomes in clinical trials. This in itself offers an opportunity to potentiate effective treatments for many groups of people, when diverse variables like genetic ancestry are consciously included into study design. This Perspective highlights the need for conscious inclusion of genetic ancestry in preclinical cancer tissue engineering, especially when it pertains to determining therapeutic outcomes. |
| first_indexed | 2024-12-12T03:37:44Z |
| format | Article |
| id | doaj.art-34cbe0e168cc4497a9d541d37cf83439 |
| institution | Directory Open Access Journal |
| issn | 1754-8403 1754-8411 |
| language | English |
| last_indexed | 2024-12-12T03:37:44Z |
| publishDate | 2022-05-01 |
| publisher | The Company of Biologists |
| record_format | Article |
| series | Disease Models & Mechanisms |
| spelling | doaj.art-34cbe0e168cc4497a9d541d37cf834392022-12-22T00:39:45ZengThe Company of BiologistsDisease Models & Mechanisms1754-84031754-84112022-05-0115510.1242/dmm.049520049520How inclusive are cell lines in preclinical engineered cancer models?Shreya Raghavan0 Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, 5016 Emerging Technologies Building, College Station, TX 77843, USA Diverse factors contribute to significant and dire disparities in cancer risk and treatment outcomes. To address this, there was a call for inclusion of sex as a biological variable, which resulted in more instances of careful inclusion of sex in preclinical studies of cancer. Another variable in cancer treatment is genetic ancestry. Although this is considered explicitly in clinical research, it is considerably neglected in preclinical studies. Preclinical research can use several 3D in vitro model systems, such as spheroids/organoids, xenografts, or other bioengineered systems that combine biomaterials and cellular material. Ultimately, the cellular base for all of these in vitro model systems is derived from human cell lines or patient samples, to investigate mechanisms of cancer and screen novel therapeutics, all of which aim to maximize successful outcomes in clinical trials. This in itself offers an opportunity to potentiate effective treatments for many groups of people, when diverse variables like genetic ancestry are consciously included into study design. This Perspective highlights the need for conscious inclusion of genetic ancestry in preclinical cancer tissue engineering, especially when it pertains to determining therapeutic outcomes.http://dmm.biologists.org/content/15/5/dmm049520 |
| spellingShingle | Shreya Raghavan How inclusive are cell lines in preclinical engineered cancer models? Disease Models & Mechanisms |
| title | How inclusive are cell lines in preclinical engineered cancer models? |
| title_full | How inclusive are cell lines in preclinical engineered cancer models? |
| title_fullStr | How inclusive are cell lines in preclinical engineered cancer models? |
| title_full_unstemmed | How inclusive are cell lines in preclinical engineered cancer models? |
| title_short | How inclusive are cell lines in preclinical engineered cancer models? |
| title_sort | how inclusive are cell lines in preclinical engineered cancer models |
| url | http://dmm.biologists.org/content/15/5/dmm049520 |
| work_keys_str_mv | AT shreyaraghavan howinclusivearecelllinesinpreclinicalengineeredcancermodels |